查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1863650

全球心房颤动市场：按类型、技术、疗法、终端用户和地区划分 - 市场规模、行业趋势、机会分析和预测（2025-2033 年）

Global Atrial Fibrillation Market: By Type, By Technology, By Treatment, By End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 174 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

受创新诊断和治疗方案需求不断增长的驱动，房颤市场正在快速发展。 2024 年，该市场收入约为 37.3209 亿美元，反映出心房颤动盛行率的上升以及先进医疗技术的日益普及。预计这一成长趋势将持续强劲，到 2033 年，市场规模预计将达到 79.1366 亿美元。这一显着增长意味着 2025 年至 2033 年的复合年增长率 (CAGR) 为 8.71%。

推动这一成长的关键因素之一是对主动侦测方法的重视，这些方法对于更有效地管理心房颤动至关重要。配备先进感测器和人工智慧诊断工具的可穿戴监测设备正在改变这种疾病的识别和监测方式。这些技术能够持续、即时地追踪心律，从而实现早期诊断和及时干预，避免併发症的发生。

市场动态

心房颤动 (AF) 市场竞争异常激烈，美敦力、波士顿科学和雅培等行业领导者不断透过各种策略措施来维持和扩大市场占有率。这些公司积极推出创新产品、进行收购并建立合作关係，以巩固其在这个快速发展领域中的地位。

例如，2025 年 5 月，全球医疗保健领导者雅培宣布推出 TactiFlex 感测器消融导管。该设备是世界上首款将柔性尖端与先进接触力技术结合的消融导管。该产品的创新之处在于提高了导管消融手术的精准性和安全性，该手术旨在靶向并消除异常电通路，是治疗心律不整的关键。

同样，强生医疗科技于2025年7月在亚太地区推出了VARIPULSE™平台，进一步拓展了其业务。该平台专为执行导管消融手术而设计，用于治疗心房颤动。心房颤动是一种常见的心律不整，其特征是由于心房内电讯号紊乱而导致的心跳不规则且通常过快。

主要成长推动因素

推动心房颤动市场成长的关键因素之一是左心耳封堵术（LAAO）装置作为一种非药物治疗方法在预防中风方面的快速普及。这些装置为中风高风险患者或有长期抗凝血治疗禁忌症或不耐受的患者提供了一种替代方案。左心耳封堵术 (LAAO) 技术的日益普及体现在手术数量的显着增长上，预计仅 2024 年就将进行 10 万例 LAAO 手术。这一激增反映了临床医生和患者对这些设备的有效性和安全性越来越有信心。

新兴机会

穿戴式健康监测技术的快速普及为心房颤动市场带来了巨大的机会。苹果和三星等领先的科技公司正在开发配备先进感测器和尖端人工智慧演算法的设备，从而实现房颤的早期检测。这些创新正在改变传统的健康监测方式，直接向使用者提供连续的即时数据，从而能够及早识别那些可能直到出现更严重症状才会被发现的心律不整。

优化障碍

心房颤动市场面临的重大挑战之一是确保患者能够公平地获得先进的消融技术。虽然这些先进疗法疗效显着，但费用高昂，这可能会限制某些患者群体获得治疗的机会，尤其是在医疗预算紧张或保险覆盖不足的地区。先进消融设备和手术的高昂价格可能会造成治疗机会不均等，使一些患者无法受益于最新的医疗技术。

目录

第一章：研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第二章：研究方法

  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 按地区划分的一手调查受访者组成
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：摘要整理：全球心房颤动市场

第四章：全球心房颤动市场概述

  • 产业价值链分析
    • 设备供应商
    • 製造商
    • 经销商
    • 最终用户
  • 行业展望
    • 新兴技术
    • 各国病例总数
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长推动因素
    • 阻碍因素
    • 挑战
    • 主要趋势
  • 新冠疫情对市场的影响评估成长趋势
  • 市场成长与展望
    • 市场收入估计与预测（2020-2033 年）
    • 价格趋势分析
  • 竞争格局概览
    • 市场集中度
    • 公司市占率分析（价值，2024 年）
    • 竞争格局图

第五章 全球心房颤动市场分析：依类型划分

  • 主要见解
  • 市场规模与预测（2020-2033 年）
    • 阵发性心房颤
    • 持续性心房颤
    • 慢性/永久性心房颤动

第六章：全球心房颤动市场分析：依技术划分

  • 主要见解
  • 市场规模及预测，2020-2033
    • MicroLife AFIB 技术
    • 混合外科导管消融术
    • 冷冻疗法

第七章：全球心房颤动市场按疗法划分的分析

  • 主要见解
  • 市场规模及预测，2020-2033
    • 诊断
    • 药物治疗

第八章：全球心房颤动市场按最终用户划分的分析

  • 主要见解
  • 市场规模及预测，2020-2033
    • 医院
    • 护理中心
    • 门诊
    • 门诊护理服务

第九章 全球心房颤动市场：依地区划分

  • 主要见解
  • 市场规模及预测，2020-2033 年
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲 (MEA)
    • 南美

第十章：北美心房颤动市场分析

  • 主要见解
  • 市场规模及预测，2020-2033 年
    • 依类型
    • 按技术
    • 依疗法
    • 按最终用户
    • 依国家/地区

第十一章：欧洲心房颤动市场分析

第十二章：亚太地区心房颤动市场分析

第十三章：中东与非洲心房颤动市场分析

第十四章：南美洲心房颤动市场分析

第15章 企业简介

  • AtriCure Inc.
  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus Inc.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • Koninklijke Philips N.V.
  • MicroPort Scientific Corporation
  • Sanofi-Aventis
  • Siemens AG
  • St. Jude Medical Inc.
  • Other Prominent Players
简介目录
Product Code: AA1222338

The atrial fibrillation market is experiencing rapid advancement, driven by increasing demand for innovative diagnostic and treatment solutions. In 2024, the market generated revenue of approximately US$ 3,732.09 million, reflecting the growing prevalence of atrial fibrillation and the expanding adoption of advanced medical technologies. This upward trajectory is expected to continue strongly, with projections estimating the market will reach a valuation of US$ 7,913.66 million by 2033. This remarkable growth corresponds to a compound annual growth rate (CAGR) of 8.71% during the forecast period from 2025 to 2033.

One of the key factors driving this growth is the prioritization of proactive detection methods, which are becoming integral to managing atrial fibrillation more effectively. Wearable monitors equipped with sophisticated sensors and artificial intelligence-powered diagnostic tools are transforming how the condition is identified and monitored. These technologies enable continuous, real-time tracking of cardiac rhythms, allowing for earlier diagnosis and timely intervention before complications arise.

Noteworthy Market Developments

The atrial fibrillation (AF) market is highly competitive, with major industry players such as Medtronic, Boston Scientific, and Abbott continually striving to maintain and expand their market share through a range of strategic initiatives. These companies actively engage in launching innovative products, pursuing acquisitions, and forming partnerships to strengthen their positions in this rapidly evolving sector.

For example, in May 2025, Abbott, a global healthcare leader, announced the launch of the TactiFlex Sensor-Enabled Ablation Catheter. This device is notable for being the world's first ablation catheter to combine a flexible tip with advanced contact force technology. The innovation behind this product enhances the precision and safety of catheter ablation procedures, which are critical for treating atrial fibrillation by targeting and eliminating the abnormal electrical pathways.

In a similar move, Johnson & Johnson MedTech expanded its footprint in the Asia-Pacific region in July 2025 with the launch of the VARIPULSE(TM) Platform. This platform is designed specifically for performing catheter ablation procedures to treat atrial fibrillation, a common cardiac arrhythmia characterized by irregular and often rapid heartbeats caused by uncoordinated electrical signals in the atria.

Core Growth Drivers

A significant driver propelling growth in the atrial fibrillation market is the rapid adoption of Left Atrial Appendage Occlusion (LAAO) devices as a non-pharmacological approach to stroke prevention. These devices offer an alternative for patients who are at high risk of stroke but may have contraindications or intolerance to long-term anticoagulant therapy. The increasing acceptance of LAAO technology is reflected in the substantial number of procedures performed, with an estimated 100,000 LAAO interventions carried out in 2024 alone. This surge underscores the growing confidence among clinicians and patients in the efficacy and safety of these devices.

Emerging Opportunity Trends

A significant opportunity within the atrial fibrillation market arises from the rapid consumer adoption of wearable technology designed for health monitoring. Leading technology companies such as Apple and Samsung have developed devices equipped with sophisticated sensors and advanced AI-driven algorithms capable of detecting atrial fibrillation at an early stage. These innovations transform traditional health monitoring by providing continuous, real-time data directly to users, enabling early identification of irregular heart rhythms that might otherwise go unnoticed until more severe symptoms emerge.

Barriers to Optimization

One of the significant challenges facing the atrial fibrillation market is ensuring equitable patient access to advanced ablation technologies, which are often expensive. These cutting-edge treatment options, while highly effective, come with substantial costs that can limit their availability to certain patient populations, particularly in regions with constrained healthcare budgets or inadequate insurance coverage. The high price point of advanced ablation devices and procedures may create disparities in treatment accessibility, preventing some patients from benefiting from the latest medical innovations.

Detailed Market Segmentation

By Type, the Chronic/Permanent Afib segment is projected to secure a commanding 48.6% share of the atrial fibrillation market, reflecting its significant impact on the overall disease burden. This dominance is closely linked to demographic trends, particularly the aging global population. As people age, the likelihood of atrial fibrillation progressing from intermittent or paroxysmal episodes to a chronic or permanent condition increases substantially. This progression is due to structural and electrical changes in the heart that accumulate over time, making permanent Afib more prevalent among older adults.

By Technology, cryotherapy is poised to dominate the atrial fibrillation market, commanding a significant 53.7% share. This strong position is largely driven by its compelling value proposition, which combines procedural efficiency with enhanced safety profiles. Cryotherapy, particularly in the form of cryoballoon ablation, has gained widespread acceptance among electrophysiologists and hospital administrators alike because it offers a highly effective treatment option that reduces the duration of procedures without compromising patient outcomes.

By Treatment, the diagnosis segment continues to hold a commanding lead in the atrial fibrillation market, accounting for over 68.7% of the total share. This dominant position reflects a broader strategic shift within the healthcare industry towards preventative care, emphasizing the importance of early and accurate detection to improve patient outcomes. Detecting atrial fibrillation at an early stage is critical, as it allows for timely intervention that can prevent severe and costly complications, such as stroke and heart failure, which are common consequences of untreated or late-diagnosed atrial fibrillation.

By End User, hospitals are poised to maintain their dominant role as the primary end-user in the atrial fibrillation market, effectively serving the vast majority of treatment demand for this condition. Their leading position is largely due to their capacity to provide the most complex and high-value interventions, particularly catheter ablation procedures, which require specialized equipment and highly trained medical teams. These advanced treatments are typically only available in hospital settings, where comprehensive care can be delivered safely and efficiently. As a result, hospitals remain the central hubs for managing atrial fibrillation, offering a wide range of services from diagnosis to advanced therapeutic interventions.

Segment Breakdown

By Type

  • Paroxysmal Afib
  • Persistent Afib
  • Chronic/Permanent Afib

By Technology

  • Microlife AFIB Technology
  • Hybrid Surgical-Catheter Ablation
  • Cryotherapy

By Treatment

  • Diagnosis
  • Electrocardiogram
  • Blood tests
  • Echocardiogram
  • Chest X-ray
  • Other (Blood tests)
  • Medication
  • Anticoagulants
  • Others

By End User

  • Hospitals
  • Care Centers
  • Outpatients
  • Ambulatory Services

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Geography Breakdown

  • North America holds a commanding position in the global atrial fibrillation market, accounting for over 39% of the total market share. This dominant stance is largely attributed to the region's substantial healthcare spending, which supports widespread access to advanced treatments and diagnostic technologies. The high procedural volumes in North America reflect a well-established healthcare system that is both capable and equipped to manage the growing number of atrial fibrillation cases. Additionally, the region benefits from a sophisticated healthcare infrastructure, including state-of-the-art medical facilities and a highly skilled workforce of cardiologists, electrophysiologists, and support staff.
  • Within North America, the United States stands out as the largest contributor to the market in 2024. This leadership is driven by several critical factors, foremost among them being the high incidence of atrial fibrillation cases in the country's aging population. The U.S. healthcare system has rapidly embraced minimally invasive ablation technologies, which have become the preferred treatment option due to their effectiveness and reduced recovery times. Furthermore, robust clinical guidelines in the U.S. strongly support early intervention for atrial fibrillation, encouraging timely diagnosis and treatment to prevent complications such as stroke and heart failure.

Leading Market Participants

  • Atri Cure Inc.
  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus Inc.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • Koninklijke Philips N.V.
  • MicroPort Scientific Corporation
  • Sanofi-Aventis
  • Siemens AG
  • St. Jude Medical Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1 Research Objective
  • 1.2 Product Overview
  • 1.3 Market Segmentation

Chapter 2. Research Methodology

  • 2.1 Qualitative Research
    • 2.1.1 Primary & Secondary Sources
  • 2.2 Quantitative Research
    • 2.2.1 Primary & Secondary Sources
  • 2.3 Breakdown of Primary Research Respondents, By Region
  • 2.4 Assumption for the Study
  • 2.5 Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Atrial Fibrillation Market

Chapter 4. Global Atrial Fibrillation Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Equipment Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Emerging Technologies
    • 4.2.2. Total Number of Cases, By Country
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
    • 4.7.3. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Atrial Fibrillation Market Analysis, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Paroxysmal Afib
    • 5.2.2. Persistent Afib
    • 5.2.3 Chronic/Permanent Afib

Chapter 6. Global Atrial Fibrillation Market Analysis, By Technology

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. Microlife AFIB Technology
    • 6.2.2. Hybrid Surgical-Catheter Ablation
    • 6.2.3. Cryotherapy

Chapter 7. Global Atrial Fibrillation Market Analysis, By Treatment

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Diagnosis
      • 7.2.1.1. Electrocardiogram
      • 7.2.1.2. Blood tests
      • 7.2.1.3. Echocardiogram
      • 7.2.1.4. Chest X-ray
      • 7.2.1.5. Other (Blood tests)
    • 7.2.2. Medication
      • 7.2.2.1. Anticoagulants
      • 7.2.2.2. Others

Chapter 8. Global Atrial Fibrillation Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Hospitals
    • 8.2.2. Care Centers
    • 8.2.3. Outpatients
    • 8.2.4. Ambulatory Services

Chapter 9. Global Atrial Fibrillation Market, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. Australia & New Zealand
      • 9.2.3.5. ASEAN
      • 9.2.3.6. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa (MEA)
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Brazil
      • 9.2.5.2. Argentina
      • 9.2.5.3. Rest of South America

Chapter 10.North America Atrial Fibrillation Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Treatment
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. Europe Atrial Fibrillation Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Technology
    • 11.2.3. By Treatment
    • 11.2.4. By End User
    • 11.2.5. By Country

Chapter 12. Asia Pacific Atrial Fibrillation Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Technology
    • 12.2.3. By Treatment
    • 12.2.4. By End User
    • 12.2.5. By Country

Chapter 13. Middle East & Africa Atrial Fibrillation Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Technology
    • 13.2.3. By Treatment
    • 13.2.4. By End User
    • 13.2.5. By Country

Chapter 14. South America Atrial Fibrillation Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Technology
    • 14.2.3. By Treatment
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Sales Composition Ratio, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 15.1. AtriCure Inc.
  • 15.2. Biosense Webster Inc.
  • 15.3. Boehringer Ingelheim GmbH
  • 15.4. Boston Scientific Corporation
  • 15.5. Bristol-Myers Squibb Corporation
  • 15.6. CardioFocus Inc.
  • 15.7. Endoscopic Technologies Inc.
  • 15.8. Johnson & Johnson Ltd.
  • 15.9. Koninklijke Philips N.V.
  • 15.10. MicroPort Scientific Corporation
  • 15.11. Sanofi-Aventis
  • 15.12. Siemens AG
  • 15.13. St. Jude Medical Inc.
  • 15.14. Other Prominent Players